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Colorectal cancer results from a series of genetic changes which
disrupt the mechanisms that normally control growth in colonic
epithelial cells (Fearon and Vogelstein, 1990; Kinzler and
Vogelstein, 1996). There is considerable epidemiological and
experimental evidence to suggest that an important environmental
factor, implicated in the genetic mutations involved in sporadic
colorectal tumorigenesis, is diet (Giovannucci and Willett, 1994)
but the precise nature of the mutagens present in the diet is unclear
(Bruce, 1987) and their relationship with the known genetic
factors is undetermined. Kinzler and Vogelstein (1996) have
suggested that mutagens may be carcinogenic not just because
they induce mutation but also because they induce substantial
cellular death with the corresponding induction of a regenerative
response (Cohen and Ellwein, 1990). They hypothesized that this
regenerative response, during which apoptotic signals must be
turned off to enable net cellular growth to occur, would enable
cells possessing mutations in growth-controlling genes to prolif-
erate, whereas non-regenerating cells possessing these mutations
would simply undergo programmed cell death. Although it is
recognized that inhibitors of apoptosis such as BCL-2 are
increased in colorectal cancer cells (Sinicrope et al, 1995) and that
the induction of apoptosis by bile acids is diminished with bile
from colorectal cancer patients (Garewal et al, 1996), evidence
that genes directly involved in regenerative processes are some-
times activated in sporadic colorectal cancer is sparse.
The pancreatic regenerating gene (REG) is one member of a
family of genes encoding at least three proteins, described in rats,
mice and humans, which bear sequence homology to calcium-
dependent lectins (Unno et al, 1993). The 166 amino-acid human
REG gene product is known as Lithostathine and this is secreted
by normal pancreatic acinar cells, but not islet cells, and belongs to
the C-type lectin family. Another member of this family is known
as pancreatitis-associated protein (PAP), the gene for which
appears to be identical with the HIP gene (expressed in hepato-
cellular, intestine and pancreas carcinoma) and codes for a 175
amino-acid protein exhibiting 49% amino-acid identity with REG
protein (Miyashita et al, 1995). These proteins have wide ranging
functions in cellular adhesion and cell-to-cell interactions. The
REG gene was initially identified during the screening of a cDNA
library constructed from regenerating pancreatic tissue in a rat
which had undergone partial pancreatectomy (Terazono et al,
1988). The human homologue of the rat reg gene is expressed in
normal human pancreas (Bartoli et al, 1993), was sequenced in
1990 (Watanabe et al, 1990), and has been localized to chromo-
some 2p12 (Lasserre et al, 1994). A preliminary tissue distribution
study using northern blot analysis suggested that REG gene
expression might occur in six of seven colorectal cancers, but not
in normal colonic mucosa from the same patients (Watanabe et al,
1990). Members of this gene family are up-regulated in human
colorectal cancer cell lines during differentiation (Bernard-Perrone
et al, 1999), this being reflected at the protein level by western
blotting studies in a small series of human colorectal cancers
(Rechreche et al, 1999). REG gene expression has also been impli-
cated in the regenerative process in gastric mucosa (Asahara et al,
1996) and its product has been detected in ductal adenocarcinoma
of the pancreas (Kimura et al, 1992). PAP is expressed in 25% of
human hepatocellular carcinomas and has been implicated in liver
cell proliferation and differentiation (Lasserre et al, 1992).
Because of the potential importance of the REG gene family
products in cellular adhesion and regenerative processes, the
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present study aimed to determine the precise frequency at which
these genes are expressed in a series of colorectal cancers. We also
aimed to determine the relationship between transcription of the
REG family of genes and clinical outcome in patients with
colorectal cancer treated by surgical resection alone without
adjuvant therapy.
MATERIALS AND METHODS
Cell lines and clinical material
Preliminary studies were undertaken to determine REG expression
in a variety of human tumour cell lines of colorectal (LoVo,
COLO320, SW480, SW948), pancreatic (PANC1), hepatic
(hepG2) and gastric (KATO-III) origin. Heparinized peripheral
venous blood was obtained from healthy volunteers and neutrophil
and mononuclear cell fractions isolated by Dextran sedimentation
and Ficoll extraction. Normal bone marrow samples were obtained
from ten patients undergoing bone marrow aspiration for investi-
gatory purposes unrelated to the presence of malignant disease.
Samples of non-ulcerated tumour edge, taken from the bowel
immediately following resection, were obtained from 142 patients
undergoing surgery for colorectal cancer of whom 83 were male
and 59 female. Their mean (±SD) age was 70 (±10) years. Fifty
five of these patients suffered from rectal cancer, the remaining 87
having colonic cancer. The TNM staging of these tumours is
shown in Table 1. Normal colonic mucosa from a point distant to
the tumour was also available from 88 of the fresh surgically
resected specimens. REG expression was determined in all 142
colorectal cancers but PAP expression was only examined in RNA
preparations from 130 of these tumours because of paucity of
material from the remaining twelve. At the time at which these
specimens were collected, no patient with stage I or II disease
received adjuvant chemotherapy and only five patients with stage
III disease underwent adjuvant therapy with 5-fluorouracil and
folinic acid. 
Normal colonic mucosa was also obtained from eight patients
undergoing colectomy for diverticular disease. A sample of fresh
normal pancreas was obtained from the resection specimen of a
young patient undergoing distal pancreatectomy for blunt trauma
to the pancreas. Fresh polyp tissue was obtained from three
patients undergoing colonoscopic resection of adenomatous
polyps. In addition, 20 colonic mucosal biopsies were obtained
from 15 patients suffering from ulcerative colitis during an active
phase of their disease and 16 mucosal biopsies were also provided
by these same patients between 1 and 6 months after their disease
had been in remission subsequent to appropriate therapy.
All specimens for RNA assay were snap-frozen in liquid
nitrogen and stored at –70°C until assay. The presence of tumour
in the malignant tissues (or absence of tumour in the ‘normal’
tissue) was confirmed histologically in all samples. The remaining
operative specimen was sent for routine histological examination
and pathological staging.
Clinical follow-up of up to 5 years duration (median 24 months,
mean 33 months, range 6–60 months) was conducted on all
patients, and in particular the clinical outcome in relation to REG
and PAP status was determined in all patients who underwent
resection which was considered to be potentially curative. Patients
who died of non-cancer-related causes were treated as censored
observations in the disease-specific survival analysis.
RNA extraction
Small samples (<10 mg) of mucosa and tumour were taken from
frozen tissue blocks, ground to powder in liquid nitrogen and
immediately suspended in 1 ml of CatrimoxTM cationic surfactant
solution (Iowa biotechnology Corp. USA). The neutrophils,
monocytes, bone marrow samples and tumour cell lines were simi-
larly treated. Particulate remains were allowed to settle for 5 min
and the supernatants aspirated to a fresh tube for further
processing. The supernatant was centrifuged for 5 min at 1000 g,
forming a detergent-bound RNA pellet. The absence of contami-
nating genomic DNA was confirmed by PCR using genomic
primers (Heatshock protein 70, accession number M11717
primers at 281…304 and 485…462 bp in the coding sequence,
respectively).
Reverse transcriptase-polymerase chain reaction
(RT-PCR).
RNA (10 ml of the above solution) was reverse transcribed and
cDNA samples underwent PCR amplification using primers for a
Table 1 REG/PAP positivity in relation to clinical parameters
Variable REG- PAP- PAP and REG-
Patients (n) positive positive positive
Total numbers studied
(REG/PAP) 142/130
Mean age (years ± S.D.) 70±10 71±10 71±97 0 ±10
Sex
Male 83/142 (58.5%) 47/83 (57%) 40/71 (56%) 24/71 (34%)
Female 59/142 (41.5%) 28/59 (47%) 38/59 (64%) 17/59 (29%)
Total 142/130 75/142 (53%) 78/130 (60%) 41/130 (31.5%)
Tumour site
Colon 87/142 (61%) 42/87 (48%) 43/75 (57%) 21/75 (28%)
Rectum 55/142 (39%) 33/55 (60%) 35/55 (64%) 20/55 (36.4%)
Tumour stage
I (T1–2N0M0) 18 12/18 (67%) 14/18 (77%) 7/18 (39%)
II (T3–4N0M0) 60 32/60 (53%) 31/55 (56%) 16/55 (29%)
III (T1–4N1–2M0) 46 23/46 (50%) 26/42 (62%) 16/42 (38%)
IV (T1–4N0–2M1) 18 8/18 (44%) 7/15 (47%) 2/15 (13%)190 RCA Macadam et al
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constitutively expressed gene (glyceraldehyde-3-phosphate dehy-
drogenase), to confirm the reproducibility of mRNA extraction
and reverse transcription. Intron-spanning primers were devised to
amplify a 283 base-pair product of REG cDNA (accession number
J054 12) (REG upper dAACATGAATTCGGGCAACC, positions
2707…2726, exon 4; REG lower dAGGAGAACTTGTCT-
TCACAA, positions 3900…3881, exon 6). Similarly, to detect
PAP (accession number L15533) transcripts, primers with the
following sequences were employed: PAP upper
dTGTCACCAAAATCCTGGACA, positions 2060…2079, exon
3; PAP lower dGGATTTCTCTCCCATGCAAA, positions
3097…3116, exon 5. Primers (20 pmol) and template (1 ml of RT
reaction product) in a final volume of 10 ml were overlaid with
mineral oil and heated to 95°C for ‘hot start’ PCR. The reaction
was initiated by the addition of 10 ml of a PCR reaction mixture, to
give Taq DNA polymerase (1 U), dNTPs (0.2 mM each,
Pharmacia), 1 ´ Taq buffer (Promega) and MgCl2 (2 mM).
Reactions proceeded in a thermal cycler for 40 cycles (denatura-
tion 60 s 95°C, annealing 60 s 55°C, extension 60 s 72°C). PCR
products were electrophoresed on 2% agarose gels containing
ethidium bromide and visualized by ultraviolet transillumination.
REG positivity was defined as the presence of a 283 bp band and
PAP as a 244 bp band in each of three independent reactions and
the presence of the control 177 bp glyceraldehyde-3-phosphate
dehydrogenase RT-PCR product. Confirmation that the observed
product produced by the above PCR was derived from the amplifi-
cation of REG 1A or PAP cDNA was confirmed by direct
sequencing using the Sequenase version 2.0 DNA sequencing kit
(Amersham, Little Chalfont, Buckinghamshire, UK).
In situ hybridization studies
Because previous tissue localization studies for PAP protein in the
digestive tract had shown no expression in normal colonic mucosa
(Masciotra et al, 1995), in situ hybridization studies for REG
mRNA only was performed. The in situ hybridization was carried
out using the Boehringer Mannheim (Lowes, East Sussex, UK)
protocol and reagents on 4 micrometer-thick microtome sectioned
OCT-embedded snap-frozen tissue samples.
PCR amplification and probe labelling
Primers incorporating T7 and T3 promoter sequences were
synthesized to amplify REG gene-specific sequences (REG
T7 dATGCTAATACGACTCACTATAGGGTGC CAGAACAT-
GAATTC, REG dAGGAGAACTTGTCTTCACAA) (REG T3
dATGCTTAACCCTCACTAAAGGGAATTGACTTGCAGACA
AA, REG dAACATGAATTCGGGC). PCR conditions were the
same for both primer pairs and were as described above under
PCR methodology. The dioxygenin (DIG) labelling reaction
contained 100–200 ng of purified PCR product, 2 ml of 10 ´
concentrated DIG RNA labelling mix, 2 ml of 10 ´ concentrated
transcription buffer, 2 ml RNA polymerase (T7 or T3) and water to
a reaction volume of 20 ml. Estimation of RNA probe yield was
carried out in a side-by-side comparison of the DIG-labelled
sample nucleic acid from each PCR amplification with the DIG-
labelled control provided in the kit.
In situ hybridization
Air-dried sections were treated with PBS containing 0.3% Triton
X-100 (Sigma), permeabilized for 30 min at 37°C with TE buffer
containing 1 mg ml–1 RNase-free Proteinase K (Boehringer
Mannheim). Sections were then fixed with PBS containing 4%
paraformaldehyde, and were then acetylated with 0.25% (v/v)
acetic anhydride (Sigma). Separate solutions were made of REG
sense and antisense DIG-labelled RNA in hybridization buffer,
and 10 ng in 30 ml of solution was added to the sections which
were then incubated at 42°C overnight in a humid chamber.
In order to digest unbound probe, sections were incubated at
37°C for 30 min in NTE buffer containing 20 mg ml–1 RNase A.
The sections were then incubated for 2 h with a 1:500 concentra-
tion of sheep anti-DIG-alkaline phosphatase (Fab fragment). A
colour solution was prepared containing nitroblue tetrazolium,
5-bromo-4-chloro-indolyl phosphate with 1 mM levamisole, and
200 ml of this solution applied to each slide which was then incu-
bated in a humidified chamber in the dark overnight, prior to
staining with 0.1% nuclear-fast red. Adjacent sections did not
undergo in situ hybridization but were stained with haematoxylin
and eosin to confirm the histological features of the tissue under
investigation.
Positive control samples for REG expression consisted of
normal, freshly resected human pancreas and samples of colorectal
cancer demonstrated to express REG on RT-PCR examination. In
situ hybridization for REG was performed on sections of tumours
which had been found to express on RT-PCR, as well as tumours
found to be negative for REG on RT-PCR, and samples of normal
colonic mucosa. Negative controls were provided by attempting
hybridization with the sense probe and by omitting any probe from
the hybridization solution.
Statistical analysis
Incidence data for REG and PAP gene transcription positivity
amongst the colorectal tumours and other tissues was analysed by
Chi-squared analysis. Kaplan-Meier survival plots were generated
for patients with or without tumour REG and/or PAP expression
and for co-expressed gene expression, and the significance of any
observed differences was determined by log-rank analysis. Cox
regression analysis was employed to determine the contribution of
clinico-pathological factors and REG and PAP mRNA expression
towards patient survival and disease-free interval after surgical
resection. Entry into the model was via the forward stepwise
(Likelihood ratio) method and overall survival was defined as the
time from surgery to the time of death. Endpoints were censored
for patients dying of causes other than metastatic colorectal cancer.
All P values for these analyses are two-sided.
RESULTS
REG and PAP expression in cell lines, neutrophils,
mononuclear cells and normal bone marrow
The colon adenocarcinoma cell line SW948 was found to express
REG and PAP mRNA and was utilized throughout as a positive
control. Other colorectal (LoVo, COLO320, SW480), pancreatic
(PANC1), hepatic (hepG2) and gastric (KATO-III) tumour cell
lines did not express either REG or PAP (Figure 1). Furthermore,
no specific products were obtained with PCR amplification of
cDNA from healthy peripheral blood neutrophils, mononuclear
cells, normal bone-marrow cells or from human total genomic
DNA. Both REG and PAP were expressed in normal pancreas.REG gene transcripts and colorectal cancer 191
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REG expression in human colorectal tissues
Analysis of the 142 primary colorectal adenocarcinoma samples
(Table 1) demonstrated that 75 of 142 tumours (53%) expressed
REG mRNA. In contrast, REG mRNA expression was detected in
only 16 of the 88 (18.1%) available normal mucosa specimens
from the same patients (P = 0.02). In all but two cases the expres-
sion in normal colonic mucosa occurred only when adjacent
tumour samples from the same patients also expressed REG.
(Figure 2). The incidence of REG positivity was higher in tumours
of rectal rather than colonic origin (60% vs 48%), but this was not
statistically significant. Within the colon, REG expression was
almost equally distributed between left- (49%) and right- (48%)
sided lesions. Thus, overall analysis of REG mRNA expression by
histological stage revealed a similar incidence of positivity at all
stages of the disease with no statistically significant association
with any particular age, gender, site of tumour origin or tumour
stage (Table 1).
Positive amplification of REG transcripts was obtained in only
one of the eight samples of colonic mucosa from the patients
undergoing colectomy for diverticular disease. None of the colonic
polyps were REG-positive. Of the colonic biopsies obtained from
patients with active ulcerative colitis, 11 of 20 were positive for
REG mRNA compared with three of 16 biopsies obtained from the
same patients when the disease was in remission and histologically
normal (Chi-squared = 4.91, P < 0.05).
PAP expression in human colorectal tissues.
Determination of PAP expression in colorectal tissues was tech-
nically successful in 130 of the 142 tumours studied for REG
expression. PAP transcripts were identified in 78 of these tumour
specimens and in 31 of 72 corresponding normal colorectal
mucosa specimens. Again, PAP positivity in normal mucosa was
only seen in samples of mucosa obtained from colons bearing PAP
-positive tumours and not in colonic mucosa from non-tumour-
bearing colons. There were no statistically significant correlations
between tumour PAP -positivity and age, sex, tumour site or stage.
In a significant proportion of tumours (32% overall) both PAP and
REG were co-expressed but again this had no significant correla-
tion with tumour stage, sex, age or site (Table 1). There was insuf-
ficient material available to determine the PAP status in the colitic
biopsies.
Correlation between tumour REG and PAP expression
and survival
Multivariate analysis of the whole group of colorectal cancer
patients revealed stage to be a significant independent determinant
of survival, as expected when death from colorectal cancer is the
event of interest and survival time is the variable (Chi-squared = P
< 0.00001). Overall, REG expression failed to emerge as a statisti-
cally significant independent variable for the whole group when
analysed in relation to survival time and death from colorectal
cancer, irrespective of whether the stage IV cases were included or
not. Kaplan–Meier curves were constructed for each of the
different pathological stages according to REG and/or PAP posi-
tivity and this revealed that in the stage III and IV groups, neither
PAP nor REG positivity had any significant impact on survival.
For all patients in stages I, II and III who underwent surgical resec-
tion with curative intent, REG positivity had a negative impact on
disease-free survival (Figure 3) as did PAP positivity in the node-
negative group, but in neither instance did this reach statistical
significance on log-rank testing. However, in the group of 78
patients with no metastases either clinically or histologically, the
expression of REG had a deleterious effect on survival on log-rank
testing (P = 0.0307) (Figure 4). Similarly, although in the total
patient group overall the expression of REG had no impact on
disease-free interval, in the 78 patients with stages I and II (T1–2,
N0M0) disease undergoing potentially curative resection, REG
positivity was the only variable in the Cox proportional hazards
model capable of independently predicting tumour recurrence (P <
0.01) with a relative risk of 4.25 (95% CI 1.008–17.81). PAP
expression had a similarly deleterious effect on survival in the
node-negative group but this was not statistically significant.
However, when the results of REG and PAP co-expression were
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Figure 1 REG RT-PCR was performed on template cDNA derived from
eight cultured cell lines. mRNA was extracted from the cultured cells and
reverse transcribed. cDNA integrity was confirmed in each sample by the
successful amplification of G3PDH (not shown). PCR was conducted with
oligonucleotide primers specific for REG and the products resolved by
agarose electophoresis as shown above where amplification of REG cDNA
yielded a 283 bp PCR product. No REG expression was detected in LoVo
(Lane 1), Colo320 (Lane 2), SW480 (Lane 3), PANC1 (Lane 4), HepG2
(Lane 5) or KATOIII (Lane 6). REG cDNA was detected only in SW948 (Lane
7). A template of water only was included as a negative control (Lane 8).
Template cDNA derived from a sporadic colon carcinoma known to express
REG and PAP was included as a positive control (Lane 9). Identical results
were obtained from PCR in which oligonucleotide primers specific for PAP
were utilized (data not shown). Separate RT-PCR reactions demonstrated
that REG cDNA was not present in cDNA derived from normal neutrophils,
monocytes or from samples of normal bone marrow (not shown).
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Figure 2 G3DPH and REG PCR on paired samples of normal colorectal
mucosa and primary adenocarcinoma from six patients undergoing colorectal
cancer resection. G3PDH PCR confirmed the integrity of reverse
transcription in 11 of 12 samples. Failure of reverse transcription in sample
5 invalidated the result of the REG PCR and repeat RNA extraction and
RT-PCR were subsequently performed on this sample. Lanes 1 and 2 Patient
1, Normal tissue and cancer tissue; Lanes 3 and 4 Patient 2, Normal tissue
and cancer tissue; Lanes 5 and 6 Patient 3, Normal (Void) and cancer tissue;
Lanes 7 and 8 Patient 4, Normal tissue and cancer tissue; Lanes 9 and 10
Patient 5, Normal tissue and cancer tissue; Lanes 11 and 12 Patient 6,
Normal tissue and cancer tissue; Lane 13, Water negative control; Lane 14,
SW948 positive control.192 RCA Macadam et al
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examined, there was a significant trend indicating a diminished
5-year survival in node-negative patients whose tumours
co-expressed REG and PAP (Figure 5) (Chi-squared = 8.46,
P = 0.037). There were insufficient patents with stage III disease
who received adjuvant chemotherapy to determine whether or not
expression of these genes had a relationship to survival with or
without adjuvant therapy.
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Figure 3 Disease-free survival of patients with stages I, II and III colorectal
cancer. The broken line represents patients with tumours that expressed
REG mRNA whereas the solid line represents patients with tumours that did
not express REG.
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Figure 4 Disease-free survival of patients with stages I and II carcinoma of
the colon and rectum. Again the broken line represents patients with tumours
that expressed REG mRNA whereas the solid line represents patients with
tumours that did not express REG.
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Figure 5 The expression of PAP mRNA by stages I and II tumours in
addition to REG mRNA distinguishes a population of patients with
histologically early stage disease who have a poor prognosis.
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Figure 6 (A) In situ hybridization using REG antisense riboprobe
demonstrating strong staining of the epithelial cell component of a well-
differentiated colon adenocarcinoma, indicating the presence of REG mRNA
(´ 100). (B) In situ hybridization using REG sense probe on a section from
the same tissue sample as in A demonstrating no specific binding of this
riboprobe to the malignant epithelium (´ 100). (C) In situ hybridization using
REG antisense probe demonstrating hybridization of the riboprobe with RNA
within tumour cells at the interface between tumour (T) and normal mucosa.
Minimal non-specific binding was observed with non-neoplastic colorectal
epithelium (´ 100).REG gene transcripts and colorectal cancer 193
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In situ hybridization studies
Sections of normal pancreas elicited the expected strong reaction
in acinar cells, but not in pancreatic islets, on in situ hybridization
with the antisense probe, but not the sense probe. Tumours found
to be REG-positive by RT-PCR elicited a strongly positive reac-
tion on in situ hybridization with the REG antisense probes. The
distribution of the hybridization product was within the epithelial-
derived tumour cells rather than the stromal or infiltrating inflam-
matory cells (Figure 6A, and 6C). Sections incubated with
negative control REG sense riboprobe failed to elicit a positive
reaction (Figure 6B). None of the RT-PCR REG-negative tumours
elicited a positive reaction with either the antisense or the sense
probes.
DISCUSSION
The initial purpose of this investigation was to seek evidence in
support of the hypothesis that regenerative processes are activated
during colorectal tumorigenesis (Kinzler and Vogelstein, 1996).
The REG gene is known to be expressed in the rat pancreas
following 90% pancreatectomy and it has been demonstrated that
REG is induced by the action of several mitogens known to induce
islet cell proliferation (Watanabe et al, 1994). The present data
show that transcription of the REG family of proteins (REG and
PAP) is a feature of many human colorectal adenocarcinomas. In
these tumours REG expression was independent of tumour stage
or site although there was a tendency for it to be more frequently
expressed in rectal cancers than those originating in the colon. The
presence of REG or PAP mRNA in normal mucosa from the
colorectal cancer patients was almost invariably associated with
the presence of a REG-positive tumour and could be explained by
contamination with viable tumour cells shed from the tumour,
since these ‘normal’ samples were always removed from macro-
scopically normal mucosa at a longitudinal resection margin. The
explanation for the presence of REG transcripts in the ‘normal’
mucosa from the one patient with diverticular disease and the two
surgical specimens apparently containing REG-negative tumours
is less obvious (see below). PAP and its protein are already known
to be present in human Paneth cells and goblet cells of the small
bowel but are undetectable in the large bowel mucosa (Masciotra
et al, 1995).
Without the data from the in situ hybridization experiments, it
could be argued that the frequency with which REG expression is
seen during the acute phases of ulcerative colitis (an inflammatory
bowel disease known to carry a significant long-term risk of the
development of dysplasia and carcinoma) suggests that it is the
inflammatory component which is the source of REG expression
in tumours. In histologically normal, quiescent colitic mucosa the
expression of REG subsided, again in keeping with an origin in the
inflammatory cell infiltrate. However, the in situ hybridization
experiments appear to exclude stromal and inflammatory cells as
the source of the REG mRNA, this being confined to the epithelial
component of the malignant tumour, with no positive reaction
being observed in the adjacent normal colonic mucosa or in RT-
PCR-negative tumours. The use of REG sense probes confirmed
the specificity of the REG antisense probes for this in situ reaction.
This was reinforced by the finding that pancreatic acinar cells also
provided a positive reaction with the antisense probe but not with
the sense probe as expected (Kimura et al, 1992).
The waxing and waning of REG expression with ulcerative
colitis disease activity may reflect activation of the epithelial
regenerative process during healing of the mucosal injury,
followed by down-regulation once healing is complete. It is recog-
nized that other alterations of gene function, such as DNA
mismatch repair, also occur in dysplastic and malignant epithelium
in chronic ulcerative colitis (Suzuki et al, 1994). At this stage, data
on the expression of REG in ulcerative colitis cannot contribute
further to this debate because specimens of dysplastic colitic
mucosa were not available during the present investigation.
However, the fact that REG mRNA was detected in one colorectal
cancer cell line but not in peripheral blood neutrophils, mononu-
clear cells (lymphocytes and monocytes) or normal bone-marrow
cells supports the hypothesis that REG expression in colorectal
cancer is not attributable to the inflammatory cell infiltrate often
seen in these tumours but that it is of carcinomatous epithelial cell
origin. Final confirmation of the translation of REG gene product
by colorectal cancer cells awaits immunohistochemical studies for
which monoclonal antibodies are currently in preparation. If the
tumour distribution of the REG gene product is confirmed
immunohistochemically then this would be consistent with a
growth-promoting role for REG in colorectal carcinoma. There is
evidence that the REG gene product may regulate rat pancreatic
islet regeneration by means of a direct trophic effect on the islet
cells or their precursors (Watanabe et al, 1994; Zenilman et al,
1996), and the protein has structural homology with the growth-
promoting lectins (Lasserre et al, 1994; Patty, 1988). Moreover,
recent data suggest that rodent REG gene expression is actually
inhibited during cellular differentiation (Zenilman et al, 1997).
These activities are entirely compatible with the notion that during
colorectal carcinogenesis, this regenerative gene is activated
during the repair response associated with mutagen-induced
colonic epithelial cell death as propounded by Kinzler and
Vogelstein (1996). This regenerative response may switch off
apoptotic signals, as is known to occur in colorectal car-
cinogenesis, (Bedi et al, 1995) and permit the survival of those
cells with mutations in other growth-promoting or metastasis-
inducing genes. Thus, those cells exhibiting both a regenerative
response and other genetic mutations would have a survival
advantage, whereas mutated cells devoid of a regenerative
response would proceed down the apoptotic pathway. At present
there is no direct evidence to indicate that the REG gene product
can directly participate in apoptotic inhibition but it will be of
interest to determine, for example, the relationship between REG
expression and that of the recently-described inhibitor of apop-
tosis, survivin (Ambrosini et al, 1997). REG is a member of a
family of at least three structurally-related genes, one of which
(PAP) has been shown to be associated with hepatocellular carci-
noma (Lasserre et al, 1994). It is of interest to find that PAP is also
expressed in a proportion of colorectal cancers whereas it is not
normally expressed in colonic mucosa. The mechanisms altering
the transcriptional control of this family of genes may also be of
interest from a therapeutic standpoint.
Few of the common molecular genetic alterations in colorectal
cancer serve as prognostic indicators of survival (Dix et al,
1994b). The immunohistochemical detection of nuclear p53 over-
expression has been variously reported as being associated with
shorter survival (Auvinen et al, 1994; Zeng et al, 1994), longer
survival (Dix et al, 1994a) or with no impact on survival (Scott
et al, 1991), while cytoplasmic p53 over-expression has been
correlated with shorter survival (Sun et al, 1992). In the proximalcolon, microsatellite instability has been reported to be an indi-
cator of good prognosis (Thibodeau et al, 1993), a paradox which
seems difficult to explain especially since allelic imbalance for
chromosome 8p appears to be associated with a survival advantage
(Halling et al, 1999). There was a significant increase in colorectal
cancer-related deaths in the sub-group of patients with stages I and
II, non-metastatic early disease whose tumours expressed REG
either alone or in combination with PAP. Furthermore, the co-
expression of REG and PAP was the only variable capable of
confidently identifying that group of patients with early stage
disease who were destined to develop recurrence despite ‘curative’
surgery, although the confidence intervals for these data are wide
and limit the statistical power of the analysis. However, if this
observation is confirmed in a larger series then it will be of partic-
ular importance because of the potential to discern those patients
with histologically non-metastatic disease who are at high risk of
recurrence and who might benefit from the administration of adju-
vant chemo- or radiotherapy. Such treatment is undoubtedly effec-
tive for patients with node-positive colon cancer (Moertel et al,
1995) in whom the recurrence rate is as high as 70% and for whom
the potential survival advantages of chemotherapy outweigh the
risks and costs of over-treating the remaining 30% who will not
develop recurrent disease. Similar arguments surround the use of
radiotherapy for rectal cancer (Minsky, 1997). However, the indis-
criminate administration of such therapy to the 90% or 70% of
patients with stages I and II colorectal cancer respectively who
will not develop recurrent disease, is rather more controversial. In
this group, it has become a major clinical goal to distinguish those
patients who are at high risk of developing recurrent disease from
the majority who will not, so as to avoid the costs and toxicity of
adjuvant therapy in the latter and concentrate resources on the
former. It is possible that the expression of REG and PAP and
possibly other members of this gene family may provide the prog-
nostic marker which identifies such high-risk patients and allows
this therapeutic goal to be realised. However, RT-PCR is imprac-
tical for routine clinical use and we are currently examining the
possibilities of immunohistochemistry in order to confirm these
data and enable the clinical application of these findings.
In conclusion, this study provides evidence that the activation of
a regenerative process plays an oncogenic role in a significant
proportion of human colorectal cancers. The manifestation of this
regenerative process in the form of transcription of the REG gene
family permits the identification of a group of patients who are at
high risk of developing recurrent colorectal cancer following
‘curative surgery’ for apparently non-metastasizing disease and
who may potentially benefit from the administration of adjuvant
therapy.
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